Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine Transdermal Patch in Alzheimer's Disease
NCT00099242Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2003
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of rivastigmine in Alzheimer's disease (AD) (4 arms), sponsored by Novartis. Primary endpoints: Change in cognition from baseline at 24 weeks and Global clinical impression of change from baseline at 24 weeks. Started Nov 2003; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00099242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099242.